Characterization of biomarkers in plasma samples from bacterial sepsis NHP and

The National Heart Lung and Blood Institute, part of the National Institutes of Health within the Department of Health and Human Services, is seeking contractors to characterize biomarkers in plasma samples from bacterial sepsis non-human primate studies and investigate their relevance to sepsis outcomes. This pre-solicitation notice indicates the agency's intent to procure analytical laboratory services focused on biomarker analysis related to sepsis research. The work involves sophisticated laboratory analysis of biological samples to identify and characterize potential biomarkers that could be predictive of sepsis outcomes in research subjects. The opportunity is categorized under Analytical Laboratory Instrument Manufacturing (NAICS 334516) and Chemical and Pharmaceutical Products Manufacturing Machinery (PSC 3650), suggesting the need for specialized laboratory equipment and analytical capabilities. Interested parties have until July 1, 2025, to respond to this pre-solicitation notice, with the posting date of June 24, 2025, providing a brief seven-day window for initial responses.

This procurement opportunity does not include any set-aside designations, making it open to all qualified contractors regardless of business size or socioeconomic status. The pre-solicitation notice does not identify any incumbent contractors or specify potential award values or budget ranges for the anticipated contract. No specific quantities of plasma samples or timelines for the biomarker characterization work are detailed in the current notice. The brief nature of this pre-solicitation suggests that more comprehensive information regarding contract scope, duration, and financial parameters will be provided in subsequent solicitation documents. Contractors interested in this specialized biomedical research opportunity should prepare for a competitive procurement process focused on analytical laboratory capabilities and sepsis research expertise.